Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 28K
6: R1 Document and Entity Information HTML 45K
8: XML IDEA XML File -- Filing Summary XML 12K
11: XML XBRL Instance -- cdlx-20240318_htm XML 14K
7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
3: EX-101.DEF XBRL Definitions -- cdlx-20240318_def XML 37K
4: EX-101.LAB XBRL Labels -- cdlx-20240318_lab XML 73K
5: EX-101.PRE XBRL Presentations -- cdlx-20240318_pre XML 38K
2: EX-101.SCH XBRL Schema -- cdlx-20240318 XSD 12K
9: JSON XBRL Instance as JSON Data -- MetaLinks 13± 19K
10: ZIP XBRL Zipped Folder -- 0001666071-24-000042-xbrl Zip 44K
(State
or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
i675 Ponce de Leon Avenue NE, Suite 4100
iAtlanta
iGeorgia
i30308
(Address
of principal executive offices, including zip code)
i(888)
i798-5802
(Registrant's telephone, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
i☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
Title of each class
Trading symbol
Name of each exchange on which registered
iCommon Stock
iCDLX
iThe
Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
i☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 7.01 REGULATION FD DISCLOSURE
As previously disclosed,
on March 18, 2024, Cardlytics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Evercore Group L.L.C., BofA Securities, Inc. and Cantor Fitzgerald & Co., as sales agents, pursuant to which the Company may issue and sell, from time to time, shares of its common stock up to a maximum aggregate offering amount of $50.0 million in “at the market” offerings (the “ATM Offering Program”). On March 18, 2024, the Company sold 3,907,600 shares of its common stock at a weighted average price per share
of $12.80, for aggregate gross proceeds of $50.0 million, pursuant to the Equity Distribution Agreement and completed the ATM Offering Program.
In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
